Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts Sells 2,431 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 2,431 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $8.06, for a total transaction of $19,593.86. Following the transaction, the chief financial officer now directly owns 283,325 shares in the company, valued at $2,283,599.50. The trade was a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Austin Aerts also recently made the following trade(s):

• On Monday, November 11th, Austin Aerts sold 7,179 shares of Sera Prognostics stock. The shares were sold at an average price of $7.32, for a total value of $52,550.28.

Sera Prognostics Stock Performance

Shares of Sera Prognostics stock opened at $6.37 on Wednesday. Sera Prognostics, Inc. has a one year low of $4.98 and a one year high of $12.35. The firm has a fifty day moving average of $7.44 and a two-hundred day moving average of $7.31. The company has a market cap of $215.13 million, a P/E ratio of -6.43 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the previous year, the company earned ($0.23) earnings per share. As a group, equities analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC increased its position in shares of Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after buying an additional 30,093 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after buying an additional 75,441 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Sera Prognostics by 8.9% during the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after purchasing an additional 47,969 shares during the period. Quest Partners LLC grew its position in shares of Sera Prognostics by 533.5% in the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares during the period. Finally, State Street Corp increased its stake in Sera Prognostics by 8.8% in the third quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after purchasing an additional 34,479 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.